Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) ("Sucampo") today announced
that Kei S. Tolliver, executive vice president at S&R Technology
Holdings, LLC, was elected to its board of directors at the annual
shareholder meeting on May 22, 2013.
"Kei brings to Sucampo's Board a deep knowledge of our company's
products as well as global experience. We believe that this expertise
will provide value to Sucampo and our shareholders as we focus on the
growth of our business and the further development of our pipeline,"
said Sucampo's Chairman, Chief Executive Officer, and Chief Scientific
Officer Ryuji Ueno, M.D., Ph.D., Ph.D.
Ms. Tolliver serves as executive vice president of S&R Technology
Holdings, LLC, whose mission is to provide support to global
entrepreneurs and new businesses, and she brings global operations and
business development expertise to Sucampo's board. She was previously
vice president of business development at Sucampo, in which she was
closely involved with Sucampo's initial public offering and the
acquisition of the company's overseas affiliates in the U.K. and Japan.
She also served as General Manager of Sucampo Pharma Europe, where she
initiated and oversaw the European clinical development of lubiprostone.
In May of 1998, she was Sucampo's first full-time employee.
Ms. Tolliver recently earned a J.D. degree with honors from the Columbus
School of Law at the Catholic University of America in Washington, D.C.
She was a member of the Catholic University Law Review and part of
Columbus Community Legal Services, which offered pro bono legal services
to individuals and families in the Washington, D.C. area.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company
focused on innovative research, discovery, development and
commercialization of proprietary drugs based on prostones. The
therapeutic potential of prostones was first discovered by Ryuji Ueno,
M.D., Ph.D., Ph.D., Sucampo's chairman, chief executive officer, chief
scientific officer, and co-founder. Prostones, naturally occurring fatty
acid metabolites that have emerged as promising compounds with unique
physiological activities, can be targeted for the treatment of unmet or
underserved medical needs. For more information, please visit www.sucampo.com.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the US and internationally and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise. Forward-looking statements
in this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
most recent Form 8-K and 10-K, which the Company incorporates by
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718